ARPA-H put up to $62.7 million behind autonomous heart-care agents
The Advanced Research Projects Agency for Health awarded funding to teams through a four-year program. The teams will build patient-facing AI for heart failure care. ARPA-H committed up to $33.7 million in the first year of the $62.7 million program. Atman Health, Tempus AI and Updoc will build tools for patients. Stanford will build a separate system that watches the agents for unsafe or unusual behavior.
Verified 2:44 AM PDT · 1 original sources
Duke and Kaiser Permanente will plan tests in hospitals, clinics and rural sites. The teams building patient agents must submit an FDA authorization package within 24 months.
The contracts fund development and testing. The FDA has not approved a product. These awards do not mean any agent can safely change a patient's treatment today. ARPA-H estimates that the program could save lives and cut annual costs by $28 billion. Those results depend on the systems working, reaching patients and changing their care.
Heart-failure treatment can require medication changes based on kidney function and blood pressure. A bad recommendation can harm a patient, even when another system watches the agent.
Shadow tests will provide the first useful evidence. In those tests, agents make recommendations but do not control care. ARPA-H and Johns Hopkins APL should publish error rates, missed escalations and differences among patient groups. The FDA submission should identify every action that remains under clinician control. Duke and Kaiser should report whether the system works with both Epic and Oracle health records before wider use.
Audit the story
Original sources
Company claims remain company claims. Follow the reporting and judge the evidence directly.
Continue the edition